Corporate Venture Funds and Strategic Partnerships: Friends, Benefactors, or Frenemies?
For biotech startups, corporate venture funds (CVCs) are often painted as a dream come true—cash with benefits. You get
The Ethics of Failure: The Uncomfortable Bedfellow
The Ethics of Failure: Biotech’s Uncomfortable Bedfellow
Failure is biotech’s least glamorous partner. It doesn’t show up
The Meeting That Achieved Nothing—and Why That’s Sometimes Okay
Modern corporate life has evolved into a peculiar form of theatre: every actor dressed in Uniqlo smart casual, each line
Everyone’s an Investor—Until It’s Time to Wire the Money
The word investor has become unmoored. It used to mean something specific: a person or institution deploying capital with an
Lonely at the Top: On the Myth and Misery of Being CEO
To outsiders, the CEO title glows with a sort of untouchable glamour. Power. Prestige. The final say. To founders, it’
Fundraising Folklore: Myths, Missteps, and Magical Thinking in Biotech
Biotech, more than most sectors, runs not just on capital—but on belief. And where belief goes, myths follow. Wrapped
Consensus Kills: Why You Should Pitch the One Thing No One Wants to Hear (Yet)
One of the oddest things about biotech investing is how often everyone agrees. We agree on the hot areas. We
The Fallacy of the One Big Exit: Why Building a Biotech Career Is Not a Lottery
The myth of the one big exit is a seductive one. It is the fairytale biotech tells itself over and
The Untapped Potential (and Perils) of Patient Advocacy in Drug Development
Patient advocacy. It sounds noble, doesn’t it? Empowering individuals to shape the medicines they desperately need, bringing the human
What Biotech Can Learn from Insurance: Actuarial Thinking in Drug Development
Biotech and insurance rarely appear in the same sentence unless one is covering the other. One traffics in breakthroughs and
